What's wrong with CME?

March 2004
CMAJ: Canadian Medical Association Journal;3/16/2004, Vol. 170 Issue 6, p917
Academic Journal
Comments on the commercial sponsorship of continuing medical education (CME) programs in Canada and the U.S. as of March 2004. Percentage of U.S. CME programs which are sponsored by pharmaceutical companies; Disadvantage of a commercially-sponsored CME program; Advice to the Canadian medical community in terms of funding CME programs.


Related Articles

  • The MONEY MAZE. Pelletier, Sue // Medical Meetings;Mar/Apr2006, Vol. 33 Issue 2, p30 

    Focuses on issues discussed at the Alliance for Continuing Medical Education (CME) Annual Conference held in San Francisco, California from January 25 to 28, 2006. Reaction of attendees to an article which calls for drug companies to stop awarding grants to CME providers; Areas of research...

  • Pfizer discontinues support of CME. Arnold, Matthew // Medical Marketing & Media;Aug2008, Vol. 43 Issue 8, p22 

    The article announces that Pfizer Inc. will discontinue its support of the continuing medical education (CME) through medical education firms in the U.S. The company notes that it will continue its support through academic medical centers and teaching hospitals, associations, medical societies...

  • Out of the Quagmire. Beals, Dean // Pharmaceutical Executive;Apr2010, Vol. 30 Issue 4, p80 

    The article emphasizes the need for the U.S. pharmaceutical industry to find an effective, unbiased model for funding continuing medical education (CME). Suggested strategies to fund CME include applying Food and Drug Administration (FDA) application user fees toward DME funding, and block grant...

  • Poll paints bleak picture of CME funding. Iskowitz, Marc // Medical Marketing & Media;Sep2005, Vol. 40 Issue 9, p22 

    Presents a survey showing the drop in the funding of continuing medical education (CME) in the U.S. Factors affecting the funding of CME; Concerns of the pharmaceutical industry over revised Standards for Commercial Support from the Accreditation Council for Continuing Medical Education;...

  • Defending Professional Independence: ACCME's Proposed New Guidelines for Commercial Support of CME. Relman, Arnold S. // JAMA: Journal of the American Medical Association;5/14/2003, Vol. 289 Issue 18, p2418 

    Reports that the Accreditation Council on Continuing Medical Education (ACCME) released a draft of proposed new and stronger standards for the commercial support of continuing medical education (CME). How without help from pharmaceutical companies, professional providers of CME would not be...

  • Choose Change. Hosansky, Tamar // Medical Meetings;Jul/Aug2005, Vol. 32 Issue 5, p8 

    Comments on the issues faced by providers of continuing medical education (CME) in the U.S. Impact of the changes made by pharmaceutical companies in the systems for awarding CME grants; Decline in commercial support for CME in 2004; Suggested funding models for CME providers.

  • Funding Forecast Looks Bright.  // Medical Meetings;Jan/Feb2007, Vol. 34 Issue 1, p9 

    The article discusses the findings of a study which examined the views of medical education and medical affairs executives on continuing medical education funding in the U.S. The study was conducted by Cutting Edge Information among executives from pharmaceutical and biotechnology companies. It...

  • CME'S OPEN GESTURE. Iskowitz, Marc // Medical Marketing & Media;Aug2007, Vol. 42 Issue 8, p36 

    The article reports on the plan of drug companies, patient groups and societies in the U.S. to provide educational grants to restore the public's trust on Continuing Medical Education (CME). Eli Lilly & Co. planned to post a clinical trial data on the Internet and to have a quarterly update on...

  • System Collapse? Passin, Steven M.; O'Brien, Susan // Medical Meetings;Sep/Oct2005, Vol. 32 Issue 6, p24 

    Suggests that continuing medical education (CME) providers in the U.S. should take steps now to develop strategies for funding their activities that do not rely solely on industry money. Highlights of the U.S. Senate investigation on major pharmaceutical companies' practices of awarding...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics